Better Functional Outcome With Stent Retrievers in Acute Stroke

Share this content:
Better Functional Outcome With Stent Retrievers in Acute Stroke
Better Functional Outcome With Stent Retrievers in Acute Stroke

WEDNESDAY, April 20, 2016 (HealthDay News) -- For patients with acute ischemic stroke, treatment with stent retrievers with quick reperfusion time is associated with improved outcomes, according to a study published online April 19 in Radiology.

Mayank Goyal, M.D., from the University of Calgary in Canada, and colleagues examined the correlation between functional independence and time to reperfusion in the Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial. One hundred ninety-six patients with disabling acute ischemic stroke were enrolled; patients were treated with intravenous tissue plasminogen activator alone or in combination with the Solitaire device.

The researchers found that a symptom onset to reperfusion time of 150 minutes in the stent retriever arm of the study correlated with a 91 percent estimated probability of functional independence, which decreased by 10 and 20 percent over the next hour and with every subsequent hour of delay, respectively. The time from arrival at the emergency department to arterial access and time to reperfusion were 90 and 129 minutes, respectively. Longer symptom onset to groin puncturing timing was seen for patients who initially arrived at a referring facility versus those who presented directly to the endovascular-capable center (P < 0.001).

"Fast reperfusion leads to improved functional outcome among patients with acute stroke treated with stent retrievers," the authors write.

Several authors disclosed financial ties to pharmaceutical and medical devices companies, including Covidien, which funded the SWIFT PRIME trial

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »